Modality
Degrader
MOA
AuroraAi
Target
KRASG12C
Pathway
Proteasome
EoEMCLRett
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
~Feb 2023
→ ~May 2024
Phase 2
Aug 2024
→ Aug 2030
Phase 2Current
NCT03160660
2,058 pts·EoE
2024-08→2030-08·Active
2,058 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-284.4y awayPh2 Data· EoE
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2030-08-28 · 4.4y away
EoE
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03160660 | Phase 2 | EoE | Active | 2058 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C |